Search

Rare Disease Spotlight: Transthyretin Amyloidosis Cardiomyopathy (ATTR‐CM) Disease Burden, Unmet Needs, and Treatment Advances
Regulatory Briefing: Marketplace Integrity and Affordability Proposed Rule
Optimizing Healthcare Outcomes: Clinical Advancements, Economic Impact of RYONCIL in Treating Pediatric SR-aGVHD
(L1) Legislative Impacts on Site of Service: What is the Big Deal?
(R1) Unlocking the Value of Real-World Evidence (RWE): Insights for Payers and Manufacturers
(W1) The Regulatory Landscape of AI in Managed Care Pharmacy: Compliance, Ethics, and Future Trends
(L3) Federal Legislative and Regulatory Update
(M3) Advancing Health Equity in Food Allergy Prevention and Treatment: Bridging Gaps in Care and Knowledge
(R3) Research Podium Session – Leveraging Real-World Data to Advance Managed Care Pharmacy Practice
(W3) Collaborative Strategies for Pharmacist Reimbursement
(M4) Future Horizons: Emerging Trends Impacting Managed Care Pharmacy
(L4) State Legislative and Regulatory Update
(R4) United in Care: A Modified Delphi Journey to Determine Meaningful Reporting Measures in Specialty Pharmacy
(W4) Innovative Managed Care Solutions in Oncology: Enhancing Outcomes While Blunting the Cost Curve
(W6) Understanding Complexities Specific to Gene Therapy and Navigating Available Management Strategies
(D6) Drug Pipeline: Traditional Pharmaceuticals (Brands and Generics)
Policy Outlook 2025: The Trump Administration and the 119th Congress
(L1) Legislative Impacts on Site of Service: What is the Big Deal?
(R1) Unlocking the Value of Real-World Evidence (RWE): Insights for Payers and Manufacturers
(W1) The Regulatory Landscape of AI in Managed Care Pharmacy: Compliance, Ethics, and Future Trends
(D1) Charting a Better Path in Managing Multiple Myeloma: Overcoming Challenges and Driving Solutions
(W2) Chimeric Antigen Receptor T-Cell (CAR-T) Therapies: Perspectives and Challenges in Managed Care
(SP1) Unlocking the Basics of Value-Based Contracting: A Hands-On Introduction
(M2) Employer Perspectives on High-Impact Drugs
(L2) Inflation Reduction Act Ripple Effects: Considerations for Patient Access and 340B

Pages